Found 4 matches for
We are looking for healthy adults to take part in the initial trial of a potential new vaccine against a virus considered to be a crucial missing element in the childhood vaccination programme. **Please note, this study has recruited a sufficient number of participants**
Neuromuscular Diseases Research
6 May 2021
Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.
Awards & Appointments Neuromuscular Diseases
9 December 2020
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
Awards & Appointments Neuromuscular Diseases Public Engagement
25 August 2020
The awardees for the second round of the University of Oxford’s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.
Neuromuscular Diseases Publication
12 August 2020
Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.